secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001835268-25-000019
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma gains FDA alignment for Phase 2 trials of rademikibart in acute asthma/COPD
--------------------------------------------------------------------------------

- FDA Type C meeting positive; agency aligned on parallel Phase 2 trials for rademikibart in acute exacerbations of asthma or COPD.
- Two placebo-controlled trials each enrolling ~160 patients with eosinophils ≥300 cells/µL; single 600 mg SC dose over 28 days.
- Initiation planned in Q2 2025; data expected in first half of 2026; cash runway into 2027.
- CEO cites prior Phase 2 maintenance data showing rapid lung function improvement within 24 hours of 600 mg dose.
- Unmet need highlighted: ~45% of patients on standard of care experience treatment failure within 28 days post-exacerbation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000019/0001835268-25-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000019/cntb-20250401.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer